Replimune CCO sells 12,000 shares in planned trade
Replimune Group Chief Commercial Officer Christopher Sarchi sold 12,000 shares of common stock in an open-market transaction.
Rhea-AI Filing Summary
Replimune Group Chief Commercial Officer Christopher Sarchi sold 12,000 shares of common stock in an open-market transaction. The sale occurred on June 1, 2026 at a weighted average price of $9.24 per share, with individual trade prices ranging from $9.15 to $9.62 per share.
After this transaction, Sarchi directly holds 180,962 Replimune shares. The filing notes that the sale was executed under a pre-arranged trading plan adopted on December 15, 2025 intended to comply with Rule 10b5-1(c), indicating it was scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 12,000 shares
Net Sell
1 txn
Insider
Sarchi Christopher
Role
Chief Commercial Officer
Sold
12,000 shs ($111K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 12,000 | $9.24 | $111K |
Holdings After Transaction:
Common Stock — 180,962 shares (Direct)
Footnotes (2)
- F1. The sales reported on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on December 15, 2025, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
- F2. The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $9.15 to $9.62 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.
Key Figures
Shares sold: 12,000 shares
Average sale price: $9.24 per share
Post-transaction holdings: 180,962 shares
+2 more
5 metrics
Shares sold
12,000 shares
Open-market sale on June 1, 2026
Average sale price
$9.24 per share
Weighted average price for 12,000 shares sold
Post-transaction holdings
180,962 shares
Shares directly held after June 1, 2026 sale
Sale price range
$9.15–$9.62 per share
Range of prices for multiple sale transactions
10b5-1 plan adoption date
December 15, 2025
Date trading plan was adopted
Key Terms
Rule 10b5-1(c), trading plan, weighted average price, open-market sale, +1 more
5 terms
Rule 10b5-1(c) regulatory
"intended to comply with Rule 10b5-1(c) under the Securities Exchange Act"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
trading plan financial
"The sales reported on this Form 4 were made by the Reporting Person pursuant to a trading plan"
A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.
weighted average price financial
"The price reported reflects a weighted average price of the Shares."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"The sales reported on this Form 4 were made by the Reporting Person"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Replimune (REPL) disclose in this Form 4?
Replimune disclosed that Chief Commercial Officer Christopher Sarchi sold 12,000 shares of common stock. The open-market sale occurred on June 1, 2026 at a weighted average price of $9.24 per share.
Was the Replimune insider sale made under a Rule 10b5-1 trading plan?
Yes. The Form 4 states the sale was made under a trading plan adopted December 15, 2025 and intended to comply with Rule 10b5-1(c), indicating the trades were pre-scheduled.
AI-generated analysis. How Rhea-AI works. Not financial advice.
